Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 350.08 Billion KRW | -3.17% |
| 2022 | 361.53 Billion KRW | -7.91% |
| 2021 | 392.58 Billion KRW | -19.41% |
| 2020 | 487.14 Billion KRW | 28.16% |
| 2019 | 380.11 Billion KRW | -0.22% |
| 2018 | 380.95 Billion KRW | -1.21% |
| 2017 | 385.61 Billion KRW | -7.41% |
| 2016 | 416.48 Billion KRW | 1.4% |
| 2015 | 410.73 Billion KRW | 0.35% |
| 2014 | 409.29 Billion KRW | 2.75% |
| 2013 | 398.35 Billion KRW | 4.92% |
| 2012 | 379.67 Billion KRW | 0.31% |
| 2011 | 378.49 Billion KRW | 17.94% |
| 2010 | 320.92 Billion KRW | 3.48% |
| 2009 | 310.15 Billion KRW | 15.47% |
| 2008 | 268.6 Billion KRW | 23.69% |
| 2007 | 217.16 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 345.82 Billion KRW | -1.22% |
| 2024 Q2 | 340.83 Billion KRW | -1.45% |
| 2023 Q1 | 387.41 Billion KRW | 7.16% |
| 2023 Q3 | 383.42 Billion KRW | 1.59% |
| 2023 FY | 350.08 Billion KRW | -3.17% |
| 2023 Q2 | 377.43 Billion KRW | -2.58% |
| 2023 Q4 | 350.08 Billion KRW | -8.7% |
| 2022 Q2 | 388.36 Billion KRW | -0.07% |
| 2022 Q4 | 361.53 Billion KRW | -4.96% |
| 2022 FY | 361.53 Billion KRW | -7.91% |
| 2022 Q1 | 388.62 Billion KRW | -1.01% |
| 2022 Q3 | 380.4 Billion KRW | -2.05% |
| 2021 Q4 | 392.58 Billion KRW | -5.64% |
| 2021 Q1 | 465.8 Billion KRW | -4.38% |
| 2021 Q2 | 427.09 Billion KRW | -8.31% |
| 2021 FY | 392.58 Billion KRW | -19.41% |
| 2021 Q3 | 416.05 Billion KRW | -2.59% |
| 2020 Q3 | 602.6 Billion KRW | 54.29% |
| 2020 Q2 | 390.56 Billion KRW | 0.08% |
| 2020 Q1 | 390.23 Billion KRW | 2.66% |
| 2020 FY | 487.14 Billion KRW | 28.16% |
| 2020 Q4 | 487.14 Billion KRW | -19.16% |
| 2019 Q1 | 392.88 Billion KRW | 3.13% |
| 2019 FY | 380.11 Billion KRW | -0.22% |
| 2019 Q4 | 380.11 Billion KRW | -2.6% |
| 2019 Q3 | 390.27 Billion KRW | -1.32% |
| 2019 Q2 | 395.5 Billion KRW | 0.67% |
| 2018 Q2 | 391.64 Billion KRW | 2.34% |
| 2018 Q4 | 380.95 Billion KRW | -2.4% |
| 2018 Q3 | 390.32 Billion KRW | -0.34% |
| 2018 FY | 380.95 Billion KRW | -1.21% |
| 2018 Q1 | 382.68 Billion KRW | -0.76% |
| 2017 Q3 | 399.68 Billion KRW | -0.25% |
| 2017 Q1 | 402.57 Billion KRW | -3.34% |
| 2017 FY | 385.61 Billion KRW | -7.41% |
| 2017 Q4 | 385.61 Billion KRW | -3.52% |
| 2017 Q2 | 400.68 Billion KRW | -0.47% |
| 2016 FY | 416.48 Billion KRW | 1.4% |
| 2016 Q3 | 422.87 Billion KRW | -1.62% |
| 2016 Q4 | 416.48 Billion KRW | -1.51% |
| 2016 Q2 | 429.85 Billion KRW | 6.18% |
| 2016 Q1 | 404.82 Billion KRW | -1.44% |
| 2015 Q3 | 405.39 Billion KRW | 0.02% |
| 2015 Q1 | 406.08 Billion KRW | -0.78% |
| 2015 FY | 410.73 Billion KRW | 0.35% |
| 2015 Q4 | 410.73 Billion KRW | 1.32% |
| 2015 Q2 | 405.33 Billion KRW | -0.19% |
| 2014 FY | 409.29 Billion KRW | 2.75% |
| 2014 Q3 | 408.58 Billion KRW | 0.93% |
| 2014 Q4 | 409.29 Billion KRW | 0.17% |
| 2014 Q2 | 404.81 Billion KRW | 0.97% |
| 2014 Q1 | 400.93 Billion KRW | 0.65% |
| 2013 Q1 | 391.55 Billion KRW | 3.13% |
| 2013 Q4 | 398.35 Billion KRW | -1.47% |
| 2013 FY | 398.35 Billion KRW | 4.92% |
| 2013 Q2 | 400.29 Billion KRW | 2.23% |
| 2013 Q3 | 404.29 Billion KRW | 1.0% |
| 2012 Q1 | 371.69 Billion KRW | 0.0% |
| 2012 Q4 | 379.67 Billion KRW | 0.0% |
| 2012 FY | 379.67 Billion KRW | 0.31% |
| 2011 Q2 | 373.07 Billion KRW | -1.41% |
| 2011 FY | 378.49 Billion KRW | 17.94% |
| 2011 Q3 | 371.04 Billion KRW | -0.55% |
| 2011 Q1 | 378.41 Billion KRW | 0.0% |
| 2010 Q2 | 329.17 Billion KRW | 3.8% |
| 2010 FY | 320.92 Billion KRW | 3.48% |
| 2010 Q3 | 313.63 Billion KRW | -4.72% |
| 2010 Q1 | 317.11 Billion KRW | 0.0% |
| 2009 Q2 | 288.25 Billion KRW | 3.68% |
| 2009 FY | 310.15 Billion KRW | 15.47% |
| 2009 Q3 | 298.33 Billion KRW | 3.5% |
| 2009 Q1 | 278.02 Billion KRW | 0.0% |
| 2008 FY | 268.6 Billion KRW | 23.69% |
| 2008 Q2 | 239.93 Billion KRW | 6.28% |
| 2008 Q1 | 225.75 Billion KRW | 0.0% |
| 2008 Q3 | 251.37 Billion KRW | 4.77% |
| 2007 Q2 | 208.72 Billion KRW | 4.92% |
| 2007 Q3 | 212.69 Billion KRW | 1.9% |
| 2007 FY | 217.16 Billion KRW | 0.0% |
| 2007 Q1 | 198.94 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -76.619% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 82.112% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 60.082% |
| HANDOK Inc. | 790.33 Billion KRW | 55.705% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -105.183% |
| Yuhan Corporation | 2814.07 Billion KRW | 87.56% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 73.382% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -274.505% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 82.066% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -46.022% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 25.34% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -204.491% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -47.996% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -0.487% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -76.619% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 16.486% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 29.952% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 40.603% |
| JW Holdings Corporation | 1176.26 Billion KRW | 70.238% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 42.728% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 75.037% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 45.727% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -127.266% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 5.556% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 28.162% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -76.619% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 67.527% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 80.225% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 45.727% |
| Yuhan Corporation | 2814.07 Billion KRW | 87.56% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 60.218% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -54.494% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 64.771% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 45.727% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 16.627% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 25.333% |
| CKD Bio Corp. | 293.78 Billion KRW | -19.163% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 31.086% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 38.035% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 12.747% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 75.956% |
| Boryung Corporation | 922.36 Billion KRW | 62.045% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 20.878% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 25.34% |
| JW Lifescience Corporation | 255.83 Billion KRW | -36.839% |